Haemodynamic effects of the flavonoid quercetin in rats revisited
Autor: | Aalt Bast, Misha F. Vrolijk, Helma van Essen, Antoon Opperhuizen, Ben J. A. Janssen |
---|---|
Přispěvatelé: | RS: FSE UCV Adaptive responses in relation to health effect and safety of nutrition, FSE Campus Venlo, RS: NUTRIM - R3 - Respiratory & Age-related Health, Farmacologie en Toxicologie, Ondersteunend personeel CD, RS: Carim - H03 ECM and Wnt signaling |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Hemodynamics
TAMSULOSIN Blood Pressure BLOOD-PRESSURE Pharmacology Rats Inbred WKY chemistry.chemical_compound Orthostatic vital signs Tamsulosin In vivo Rats Inbred SHR ANTIOXIDANT medicine heterocyclic compounds PROTECTION Phenylephrine ANTAGONIST Flavonoids CARDIOVASCULAR-DISEASE MORTALITY RISK HYPERTENSION business.industry Antagonist ANIMALS ASSOCIATION Research Papers Rats Blood pressure chemistry Quercetin business medicine.drug Research Paper |
Zdroj: | British Journal of Pharmacology, 177(8), 1841-1852. Wiley British Journal of Pharmacology |
ISSN: | 1476-5381 0007-1188 |
Popis: | Background and Purpose The flavonoid quercetin increased the in vitro potency of the alpha(1)-antagonist tamsulosin to reduce phenylephrine-dependent arterial contractions by 10-fold. To examine if this supplement-drug interaction luxates hypotensive and orthostatic events in vivo, several set of studies were conducted in spontaneously hypertensive (SHR) and normotensive (Wistar Kyoto [WKY]) rats.Experimental Approach First, in rats pretreated with quercetin or its vehicle, responses to phenylephrine and tamsulosin were examined. Second, tamsulosin-induced changes in renal, mesenteric, hindquarter and carotid conductance were compared in quercetin- and vehicle-treated rats instrumented with Doppler flow probes. Animals were also placed on a tilt table to record regional haemodynamic changes to orthostatic challenges. Third, adult SHR were instrumented with telemeters to measure 24-hr patterns of BP. Recordings were made before and during a 5-week oral treatment of quercetin. Finally, pre-hypertensive SHR were treated with quercetin from 4 to 8 weeks of age and arterial pressure was measured at 8 and 12 weeks.Key Results Pretreatment with quercetin did not influence the responses to phenylephrine and tamsulosin, in neither WKY nor SHR. While tamsulosin treatment and tilting lowered BP and increased conductance in all vascular beds, effect size was not influenced by pretreatment with quercetin. Prolonged treatment with quercetin, in either prehypertensive SHR or adult SHR with established hypertension did not lower BP.Conclusions and Implications Cumulatively, these data demonstrate that quercetin does not amplify haemodynamic effects of tamsulosin or tilting in vivo in rats and has no effect on BP development in SHR. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |